关键信息
-
基因名
CSAG3
- 应用
-
别名
CSAG2; TRAG3;; CSAG3; CSAG3AChondrosarcoma-associated gene 2/3 protein; Cancer/testis antigen 24.2; CT24.2; Taxol-resistant-associated gene 3 protein; TRAG-3
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y5P2
-
表达区间
1-48aa
-
氨基酸序列
MSRKPRASSPLSNNHPPTPKRRGSGRFPRQPGREKGPIKEVPGTKGSP
-
分子量
5.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
CSAG3 (Cancer-Testis Antigen 3) is part of a larger family of cancer-testis antigens that are typically expressed in male germ cells within the testes but are aberrantly expressed in various malignancies, including melanoma and leukemias. The unique expression pattern of CSAG3 makes it an attractive target for cancer immunotherapy, as it is largely absent in normal tissues other than the testes, minimizing potential off-target effects. Research has shown that CSAG3 can elicit an immune response, indicating its potential as a candidate for vaccine development or adoptive cell therapy. Studies have focused on understanding the immunogenicity of CSAG3, its role in tumor progression, and the mechanisms of its expression in cancer cells. Additionally, investigations have explored the pathways involved in the regulation of CSAG3 expression, providing insights into how tumors manipulate these mechanisms to evade immune surveillance. This has significant implications for the development of immunotherapeutic strategies aimed at harnessing the body’s immune system to recognize and attack cancer cells expressing CSAG3. Overall, the study of CSAG3 and other cancer-testis antigens represents a promising frontier in the search for effective cancer treatments and biomarkers for diagnosis and prognosis.
